Hypereosinophilic syndrome
MONDO:0015691Hypereosinophilic syndrome (HES) constitutes a rare and heterogeneous group of disorders, defined as persistent and marked blood eosinophilia and/or tissue eosinophilia associated with a wide range of clinical manifestations reflecting eosinophil-induced tissue/organ damage.
Also known as: HES, hypereosinophilic disease, hypereosinophilic disorder, hypereosinophilic syndrome, eosinophilia
57 clinical trials for this condition and its sub-types, 19 tagged with Hypereosinophilic syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Hypereosinophilic syndrome
-
Pulmonary eosinophilia 30 trials
1 sub-type
-
1 sub-type
-
Secondary hypereosinophilic syndrome 0 trials · 1 incl. sub-types
1 sub-type
-
Eosinophilia-myalgia syndrome 0 trials
-
Primary hypereosinophilic syndrome 0 trials
-
Can a new injection breathe life into COPD treatment?
Disease control CompletedThis study looks at whether dupilumab, an injectable medication, can improve lung function and reduce symptoms in adults with COPD who have a specific type of inflammation. The researchers are reviewing medical records from patients who received dupilumab as part of routine care,…
Sponsor: Azienda Ospedaliera di Perugia • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New hope for kids with rare blood disorder: drug may cut flares and steroid use
Disease control CompletedThis study tested the drug mepolizumab in 16 children aged 6 to 17 with hypereosinophilic syndrome (HES), a rare condition causing too many eosinophils (a type of white blood cell). The goal was to see if mepolizumab could reduce disease flares and lower the need for steroids ove…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New COPD treatment cuts hospital returns in severe cases
Disease control CompletedThis study tested whether a drug called mepolizumab, given after a severe COPD flare-up that required hospital care, could prevent future hospital stays or death. It involved 238 adults with eosinophilic COPD (a type with high levels of certain white blood cells). Participants re…
Phase 2/3 • Sponsor: University of Leicester • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Air purifiers put to the test for COPD relief
Disease control CompletedThis study looked at whether using a HEPA air purifier at home can improve lung health in adults with a type of COPD called eosinophilic COPD. 178 people took part, with half getting real purifiers and half getting fake ones. The main goal was to see if the purifiers helped with …
Sponsor: Beth Israel Deaconess Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Drug dasatinib tested for rare blood cancers
Disease control CompletedThis study tested the drug dasatinib in 68 adults with several types of blood and bone marrow disorders, including certain leukemias, myelofibrosis, and mastocytosis. The goal was to see if dasatinib could help control the disease and to check its safety. Participants took dasati…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New algorithm aims to speed up diagnosis of mysterious high white blood cell counts
Knowledge-focused CompletedThis study tested a decision algorithm to help doctors diagnose the cause of eosinophilia (high levels of a type of white blood cell). The algorithm guides which tests to do and in what order. Researchers enrolled 53 patients and measured how many followed the algorithm correctly…
Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
New clues to spot a rare blood disorder
Knowledge-focused CompletedThis study looked for new biological markers to help diagnose hypereosinophilic syndrome (HES), a rare condition where too many eosinophils (a type of white blood cell) cause damage. Researchers compared blood samples from 41 people with HES, those with other causes of high eosin…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC